Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Spatz

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Oncotarget|November 23, 2018
Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLCHangjun Wang, Alan Spatz
Molecular Oncology|May 28, 2014
From biomarker development towards implementation of multidimensional biomarker panels in a clinical settingLéon C van Kempen, Alan Spatz
Molecular Oncology|April 22, 2011
Melanoma--the pieces of the puzzle finally start coming together! PrefaceAlan Spatz, Alexander M M Eggermont
Lancet (London, England)|September 24, 2013
Cutaneous melanomaAlexander M M Eggermont, Alan Spatz, Caroline Robert
Current Opinion in Oncology|February 24, 2010
The biology behind prognostic factors of cutaneous melanomaAlan Spatz, Gerald Batist, Alexander M M Eggermont
Melanoma Research|March 9, 2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanomaGuy Namir, Mounib Elchebly, Andreas I Papadakis, et al.
Molecular Oncology|April 15, 2011
The dual role of the X-linked FoxP3 gene in human cancersMargaret Redpath, Bin Xu, Leon C van Kempen, et al.
Current Opinion in Oncology|January 12, 2012
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?Alexander M M Eggermont, Alan Spatz, Vladimir Lazar, et al.
Discovery Medicine|July 31, 2010
The biology of melanoma prognostic factorsAlan Spatz, Nathalie Stock, Gerald Batist, et al.
Melanoma Management|September 8, 2018
Molecular pathology of cutaneous melanomaLéon C van Kempen, Margaret Redpath, Caroline Robert, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Oncotarget|November 23, 2018
Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLCHangjun Wang, Alan Spatz
Molecular Oncology|May 28, 2014
From biomarker development towards implementation of multidimensional biomarker panels in a clinical settingLéon C van Kempen, Alan Spatz
Molecular Oncology|April 22, 2011
Melanoma--the pieces of the puzzle finally start coming together! PrefaceAlan Spatz, Alexander M M Eggermont
Lancet (London, England)|September 24, 2013
Cutaneous melanomaAlexander M M Eggermont, Alan Spatz, Caroline Robert
Current Opinion in Oncology|February 24, 2010
The biology behind prognostic factors of cutaneous melanomaAlan Spatz, Gerald Batist, Alexander M M Eggermont
Melanoma Research|March 9, 2026
FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanomaGuy Namir, Mounib Elchebly, Andreas I Papadakis, et al.
Molecular Oncology|April 15, 2011
The dual role of the X-linked FoxP3 gene in human cancersMargaret Redpath, Bin Xu, Leon C van Kempen, et al.
Current Opinion in Oncology|January 12, 2012
Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?Alexander M M Eggermont, Alan Spatz, Vladimir Lazar, et al.
Discovery Medicine|July 31, 2010
The biology of melanoma prognostic factorsAlan Spatz, Nathalie Stock, Gerald Batist, et al.
Melanoma Management|September 8, 2018
Molecular pathology of cutaneous melanomaLéon C van Kempen, Margaret Redpath, Caroline Robert, et al.
Pageof 8